ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for imuc
0.480
+0.007 (1.44%)
Jun 2 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.47 - 0.49
52 week 0.43 - 1.45
Open 0.47
Vol / Avg. 323,428.00/595,369.00
Mkt cap 43.48M
P/E     -
Div/yield     -
EPS -0.12
Shares 90.25M
Beta 0.74
Inst. own 17%
Aug 5, 2015
Q2 2015 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 26, 2015
ImmunoCellular Therapeutics Ltd Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
May 28, 2015
ImmunoCellular Therapeutics Ltd at Marcum MicroCap Conference
May 12, 2015
Q1 2015 ImmunoCellular Therapeutics Ltd Earnings Call - Webcast
May 11, 2015
Q1 2015 ImmunoCellular Therapeutics Ltd Earnings Release
May 7, 2015
ImmunoCellular Therapeutics Ltd at (NAIC), PR Newswire and BetterInvesting Investor Conference
Mar 12, 2015
Q4 2014 ImmunoCellular Therapeutics Ltd Earnings Call - Webcast
Mar 10, 2015
ImmunoCellular Therapeutics Ltd at ROTH Conference
Mar 9, 2015
Q4 2014 ImmunoCellular Therapeutics Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -18.39% -34.66%
Return on average equity -20.54% -37.69%
Employees 4 -
CDP Score - -

Address

23622 Calabasas Rd Ste 300
CALABASAS, CA 91302-1672
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company’s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient’s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

Officers and directors

John S. Yu M.D. Chairman of the Board, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Andrew Gengos President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 62
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 55
Bio & Compensation  - Reuters